Cox-2 Plays a Vital Role in the Impaired Anxiety Like Behavior in Colchicine Induced Rat Model of Alzheimer Disease

Table 1

The latency of first entry to the inner area in an elevated open space with a novel object (for anxiety status) of different experimental groups of rats.

Groups	Day 14	Day 21
Control	0.09 0.34	0.02 0.29
Control + E (10 mg/kg)	0.07 0.30	0.06 0.27
Control + E (20 mg/kg)	0.06 0.20	0.08 0.22
Control + E (30 mg/kg)	0.07 0.34	0.06 0.28
Sham	0.08 0.36	0.09 0.30
Sham + E (10 mg/kg)	0.08 0.34	0.04 0.28
Sham + E (20 mg/kg)	0.07 0.32	0.08 0.31
Sham + E (30 mg/kg)	0.09 0.34	0.06 0.29
AD	3.73 2.00	6.11 1.47
AD + E (10 mg/kg)	0.98 0.36	0.26 0.02
AD + E (20 mg/kg)	0.72 0.03	0.13 0.01
AD + E (30 mg/kg)	0.33 0.01	0.11 0.14

cAD versus control/sham operated rats at day 14 (), cAD versus control/sham operated rats at day 21 (), cAD versus etoricoxib treated cAD at all the doses at day 14 (), and cAD versus etoricoxib treated cAD at all the doses at day 21 (). Control + E (10 mg/kg): control rats treated with 10 mg/kg body weight of etoricoxib, control + E (20 mg/kg): control rats treated with 20 mg/kg body weight of etoricoxib, control + E (30 mg/kg): control rats treated with 30 mg/kg body weight of etoricoxib, sham + E (10 mg/kg): sham operated rats treated with 10 mg/kg body weight of etoricoxib, sham + E (20 mg/kg): sham operated rats treated with 20 mg/kg body weight of etoricoxib, sham + E (30 mg/kg): sham operated rats treated with 30 mg/kg body weight of etoricoxib, AD: intracerebroventricular colchicine injected Alzheimer disease rats, AD + E (10 mg/kg): AD rats treated with 10 mg/kg body weight of etoricoxib, AD + E (20 mg/kg): AD rats treated with 20 mg/kg body weight of etoricoxib, and AD + E (30 mg/kg): AD rats treated with 30 mg/kg body weight of etoricoxib. Values are expressed in mean SEM ( in each group).